Healthcare provider profile · identity verified

Mark Quinlan, M.D.

Family Practice · OMAHA, NE · NPI 1588718696

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	288	80
Levothyroxine Sodium	Levothyroxine Sodium	265	62
Amlodipine Besylate	Amlodipine Besylate	237	68
Simvastatin	Simvastatin	163	42
Metoprolol Succinate	Metoprolol Succinate	139	43
Omeprazole	Omeprazole	128	35
Rosuvastatin Calcium	Rosuvastatin Calcium	126	37
Metformin Hcl	Metformin Hcl	125	33
Losartan Potassium	Losartan Potassium	115	32
Alendronate Sodium	Alendronate Sodium	106	32
Tamsulosin Hcl	Tamsulosin Hcl	105	29
Alprazolam	Alprazolam	96	21
Sertraline Hcl	Sertraline Hcl	89	28
Tramadol Hcl	Tramadol Hcl	85	21
Gabapentin	Gabapentin	83	20
Lisinopril	Lisinopril	71	19
Pravastatin Sodium	Pravastatin Sodium	69	19
Allopurinol	Allopurinol	68	18
Hydrochlorothiazide	Hydrochlorothiazide	67	19
Pantoprazole Sodium	Pantoprazole Sodium	65	17
Mounjaro	Tirzepatide	64	11
Prednisone	Prednisone	63	39
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	61	18
Potassium Chloride	Potassium Chloride	61	19
Eliquis	Apixaban	58	12
Montelukast Sodium	Montelukast Sodium	58	16
Zolpidem Tartrate	Zolpidem Tartrate	51	13
Furosemide	Furosemide	47	16
Duloxetine Hcl	Duloxetine Hcl	46	12
Trazodone Hcl	Trazodone Hcl	46	15
Donepezil Hcl	Donepezil Hcl	44	12
Meloxicam	Meloxicam	44	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	43	12
Telmisartan	Telmisartan	42	12
Trulicity	Dulaglutide	42	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	40	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	39	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	38	15
Atenolol	Atenolol	36	suppressed
Carvedilol	Carvedilol	33	suppressed
Celecoxib	Celecoxib	33	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	32	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	31	suppressed
Fenofibrate	Fenofibrate	31	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	30	20
Pregabalin	Pregabalin	30	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	27	22
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	20
Clonazepam	Clonazepam	26	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Breo Ellipta	Fluticasone/Vilanterol	25	suppressed
Diazepam	Diazepam	25	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	25	suppressed
Oxycodone Hcl	Oxycodone Hcl	25	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Synthroid	Levothyroxine Sodium	24	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	23	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	23	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Ozempic	Semaglutide	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Glimepiride	Glimepiride	18	suppressed
Myrbetriq	Mirabegron	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	17	suppressed
Diclofenac Sodium	Diclofenac Sodium	17	suppressed
Famotidine	Famotidine	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	11
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	17	suppressed
Buspirone Hcl	Buspirone Hcl	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Propranolol Hcl Er	Propranolol Hcl	16	suppressed
Azithromycin	Azithromycin	15	15
Estradiol	Estradiol	15	suppressed
Eszopiclone	Eszopiclone	15	suppressed
Finasteride	Finasteride	15	suppressed
Nebivolol Hcl	Nebivolol Hcl	15	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	15	suppressed
Valsartan	Valsartan	14	suppressed
Fluticasone Propionate	Fluticasone Propionate	13	suppressed
Niacin Er	Niacin	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	13	13
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Testosterone	Testosterone	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	12	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Terbinafine Hcl	Terbinafine Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Januvia	Sitagliptin Phosphate	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error